Syncom Formulations (India) Limited
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and su… Read more
Syncom Formulations (India) Limited - Asset Resilience Ratio
Syncom Formulations (India) Limited (SYNCOMF) has an Asset Resilience Ratio of 31.53% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Syncom Formulations (India) Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Syncom Formulations (India) Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0% |
| Short-term Investments | ₹1.44 Billion | 31.53% |
| Total Liquid Assets | ₹1.44 Billion | 31.53% |
Asset Resilience Insights
- Very High Liquidity: Syncom Formulations (India) Limited maintains exceptional liquid asset reserves at 31.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Syncom Formulations (India) Limited Industry Peers by Asset Resilience Ratio
Compare Syncom Formulations (India) Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Syncom Formulations (India) Limited (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Syncom Formulations (India) Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 21.59% | ₹892.16 Million | ₹4.13 Billion | +4.74pp |
| 2024-03-31 | 16.85% | ₹681.82 Million | ₹4.05 Billion | -1.68pp |
| 2023-03-31 | 18.53% | ₹700.17 Million | ₹3.78 Billion | +5.54pp |
| 2022-03-31 | 12.99% | ₹400.31 Million | ₹3.08 Billion | -11.47pp |
| 2021-03-31 | 24.46% | ₹713.42 Million | ₹2.92 Billion | +24.26pp |
| 2020-03-31 | 0.20% | ₹3.62 Million | ₹1.81 Billion | -0.09pp |
| 2019-03-31 | 0.30% | ₹5.11 Million | ₹1.73 Billion | -2.72pp |
| 2018-03-31 | 3.01% | ₹51.49 Million | ₹1.71 Billion | +2.63pp |
| 2017-03-31 | 0.38% | ₹6.90 Million | ₹1.80 Billion | +0.31pp |
| 2015-03-31 | 0.08% | ₹1.07 Million | ₹1.38 Billion | -1.23pp |
| 2006-03-31 | 1.31% | ₹6.20 Million | ₹473.07 Million | -- |